Clinical Trial Detail

NCT ID NCT01928394
Title A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

ovarian cancer

stomach cancer

triple-receptor negative breast cancer

pancreatic cancer

lung small cell carcinoma

urinary bladder cancer

Therapies

Ipilimumab + Nivolumab

Cobimetinib + Ipilimumab + Nivolumab

Nivolumab

Age Groups: adult senior

No variant requirements are available.